Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first line treatment of patients with metastatic colorectal cancer - the AFFIRM study

In the AFFIRM study, the addition of aflibercept to mFOLFOX6 did not demonstrate a benefit in first-line therapy in patients with mCRC but higher toxity.

from Cancer via ola Kala on Inoreader http://ift.tt/1QjahO3
via IFTTT